Short Communication
Kozhakhmetov SS, Kushugulov
Abstract
Rosuvastatin is one of the most effective lipid-lowering drugs. Nevertheless its activity varies in different populations. Important role in this belongs to ABCG2. The objective of this study was to determine the impact of ABCG2 genotype on therapeutic effect of rosuvastatin in Kazakh population. This study included 82 Kazakh patients with metabolic disorder undergoing 10 -20 mg/day of rosuvastatin therapy for 12 weeks. Our findings indicated that people with 421AA genotype had higher response to the drug. The frequency of minor alleles in the studied group was 29.5%.